Jorge DiMartino

2.1k total citations
42 papers, 1.2k citations indexed

About

Jorge DiMartino is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jorge DiMartino has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 18 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Jorge DiMartino's work include Acute Myeloid Leukemia Research (18 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Protein Degradation and Inhibitors (7 papers). Jorge DiMartino is often cited by papers focused on Acute Myeloid Leukemia Research (18 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Protein Degradation and Inhibitors (7 papers). Jorge DiMartino collaborates with scholars based in United States, United Kingdom and Spain. Jorge DiMartino's co-authors include Michael L. Cleary, Paul M. Ayton, Licia Selleri, Sara Álvarez, Yi Zheng, José A. Cancelas, Michael Jansen, James C. Mulloy, Juan C. Cigudosa and Catherine Fox and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Jorge DiMartino

41 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jorge DiMartino United States 14 829 588 217 140 137 42 1.2k
Aniruddha J. Deshpande United States 19 1.4k 1.6× 761 1.3× 160 0.7× 129 0.9× 159 1.2× 52 1.7k
Silvia De Matteis Italy 8 884 1.1× 593 1.0× 119 0.5× 130 0.9× 97 0.7× 10 1.2k
Allison Mayle United States 10 788 1.0× 462 0.8× 141 0.6× 134 1.0× 66 0.5× 13 1.1k
Nadine Mayotte Canada 21 852 1.0× 563 1.0× 186 0.9× 179 1.3× 49 0.4× 38 1.3k
Lara Tickenbrock Germany 18 1.0k 1.2× 715 1.2× 229 1.1× 330 2.4× 88 0.6× 28 1.5k
Paloma García United Kingdom 18 745 0.9× 271 0.5× 248 1.1× 110 0.8× 45 0.3× 41 1.1k
Frank Breitenbuecher Germany 18 728 0.9× 811 1.4× 278 1.3× 393 2.8× 123 0.9× 33 1.5k
Anabel Heiniger Spain 21 1.1k 1.3× 416 0.7× 185 0.9× 142 1.0× 182 1.3× 23 1.5k

Countries citing papers authored by Jorge DiMartino

Since Specialization
Citations

This map shows the geographic impact of Jorge DiMartino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge DiMartino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge DiMartino more than expected).

Fields of papers citing papers by Jorge DiMartino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge DiMartino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge DiMartino. The network helps show where Jorge DiMartino may publish in the future.

Co-authorship network of co-authors of Jorge DiMartino

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge DiMartino. A scholar is included among the top collaborators of Jorge DiMartino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge DiMartino. Jorge DiMartino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mita, Monica, Alain C. Mita, Miguel A. Villalona‐Calero, et al.. (2024). Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors. Cancer Research. 84(9_Supplement). PO4–18. 1 indexed citations
2.
Villalona‐Calero, Miguel A., Monica Mita, Alain C. Mita, et al.. (2024). Abstract B112: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors. Cancer Research. 84(5_Supplement_2). B112–B112. 1 indexed citations
3.
Villalona‐Calero, Miguel A., Glenn J. Hanna, Mark Agulnik, et al.. (2024). Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3102–3102. 7 indexed citations
4.
5.
6.
Villalona‐Calero, Miguel A., Monica Mita, Alain C. Mita, et al.. (2023). Abstract B159: A first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity. Molecular Cancer Therapeutics. 22(12_Supplement). B159–B159. 4 indexed citations
7.
Lin, Tara L., Richard E. Cutler, Elizabeth Olek, et al.. (2023). Responses in patients with AML and treated with entospletinib monotherapy.. Journal of Clinical Oncology. 41(16_suppl). e19010–e19010. 1 indexed citations
8.
Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers. Cancer Research. 82(12_Supplement). 2564–2564. 3 indexed citations
9.
Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2565: CDK9 inhibitor KB-0742 is active in preclinical models of small-cell lung cancer. Cancer Research. 82(12_Supplement). 2565–2565. 1 indexed citations
10.
MacBeth, Kyle J., Vivek S. Chopra, Lin Tang, et al.. (2021). Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Experimental Hematology. 98. 47–52.e6. 8 indexed citations
11.
Hoff, Daniel D. Von, Drew Rasco, Elisabeth I. Heath, et al.. (2018). Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research. 24(17). 4072–4080. 27 indexed citations
12.
Rasco, Drew, Kyriakos P. Papadopoulos, Michael Pourdehnad, et al.. (2018). A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clinical Cancer Research. 25(1). 90–98. 74 indexed citations
13.
Raimondi, Alejandra, Christine R. Klaus, Jeffrey Keats, et al.. (2015). Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in MLL-rearranged leukemia cell lines. Molecular Cancer Therapeutics. 14(12_Supplement_2). B82–B82. 2 indexed citations
14.
15.
Wei, Jun-Ping, Mark Wunderlich, Catherine Fox, et al.. (2008). Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia. Cancer Cell. 13(6). 483–495. 238 indexed citations
16.
DiMartino, Jorge, Norman J. Lacayo, Y. Ravindranath, et al.. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 20(3). 426–432. 70 indexed citations
17.
DiMartino, Jorge, et al.. (2002). The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood. 99(10). 3780–3785. 108 indexed citations
18.
DiMartino, Jorge, T. R. Miller, Paul M. Ayton, et al.. (2000). A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 96(12). 3887–3893. 86 indexed citations
19.
DiMartino, Jorge, T. R. Miller, Paul M. Ayton, et al.. (2000). A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 96(12). 3887–3893. 8 indexed citations
20.
Welte, Karl, Jochen Buck, James P. Di Santo, et al.. (1990). A novel autoregulatory cytokine is required for the regulation of autoaggressive responses. Human Immunology. 27(3). 254–264. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aniruddha J. Deshpande Breakdown of academic impact, for papers by Silvia De Matteis Breakdown of academic impact, for papers by Allison Mayle Breakdown of academic impact, for papers by Nadine Mayotte Breakdown of academic impact, for papers by Lara Tickenbrock Breakdown of academic impact, for papers by Paloma García Breakdown of academic impact, for papers by Frank Breitenbuecher Breakdown of academic impact, for papers by Anabel Heiniger
Rankless by CCL
2026